Professor Hisham Mehanna
InHANSE, Institute of Cancer and Genomic Sciences, University of Birmingham
Professor Mehanna is the Chair of Head and Neck Surgery, and Director of InHANSE, at the University of Birmingham.
Hisham’s clinical interests are recurrence head and neck cancer surgery and thyroid and minimal access parathyroid surgery.
Hisham has a keen interest in clinical and translational research, heading a research team of 20 researchers, and holding over £10million in research grants. The main areas of his research are Human Papillomavirus-associated head and neck cancer and thyroid cancer. His research themes are drug development and redeployment, biomarkers of treatment response and early and late phase clinical trials in head and neck cancer. He is chief investigator of several multicentre and multinational clinical trials, including the PET NECK trial, published in the NEJM in 2016.
He is currently President of the British Association of Head Neck Oncologists (BAHNO) and past Chair of the Research Committee of BAHNO, the UK’s multi-disciplinary professional body, and past Chair of the UK’s National Cancer Research Institute’s head and neck group, responsible for all head neck cancer research in the UK.
Clinical trials that change patient care and the lessons learnt
We will give examples of studies in head and neck cancer that have changed patient care, and the lessons learnt in running these studies.
EVEN MORE SEMINARS
Mr Hamish Clouston The Christie NHS Foundation Trust
Surgical Management of Advanced Colonic and Rectal Malignancies.
Dr Shanmugasundaram Ramkumar University Hospital Southampton NHS Foundation Trust
Radiotherapy developments in management of recurrent rectal cancers
Dr Qamar Ghafoor University Hospital Birmingham
Stereotactive Radiotherapy Treatment for Primary Lung Cancers, and Oligometastasis to the Lungs.
Dr Catherine Coyle Christie Hospital NHS Foundation Trust
Prostate Cancer- the non surgical oncologists view
Dr Natalie Cook University of Manchester/Christie NHS Foundation Trust
Early phase trial options in prostate cancer